Bausch + Lomb and Sanoculis Announce Strategic Agreements Designed to Address Unmet Needs in Glaucoma

Bausch + Lomb has acquired a stake in Sanoculis and entered into an exclusive European distribution agreement for the minimally invasive surgical procedure MIMS®

VAUGHAN, ON and TEL AVIV, Israel, July 28, 2022 /PRNewswire/ — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better , and Sanoculis, an Israeli ophthalmic medical device startup, today announced that it has entered into strategic agreements aimed at addressing unmet needs in glaucoma. The companies have entered into an exclusive European distribution agreement for the Sanoculis Minimally Invasive Microsclerostomy (“MIMS®“), an innovative minimally invasive surgical procedure for the treatment of glaucoma. In addition, Bausch + Lomb has taken an equity stake in Sanoculis as part of a Series C funding round.

According to the World Glaucoma Association, glaucoma is the most common cause of irreversible blindness, and an estimated 79.6 million people had glaucoma in 2020, a number that is expected to rise to 111.8 million by 2040.1 MIMS® is a stentless, simple and rapid glaucoma treatment that effectively lowers intraocular pressure without the need for invasive surgery. MIMS®which is CE marked, creates a sclerocorneal drainage channel during surgery, eliminating the need to implant a stent in the eye as with existing stent procedures.

“It is estimated that the prevalence of glaucoma will continue to increase dramatically over the next nearly 20 years, and there remains a real need for new and alternative treatment options. Through our distribution agreement and our stake in Sanoculis, we reinforce our commitment to researching and making available new glaucoma treatment options for our customers and patients,” said Joseph C. Papa, CEO, Bausch + Lomb. “As a global leader in eye health with a fully integrated eye care portfolio, Bausch + Lomb remains committed to holistically addressing eye health issues, especially in areas of persistent unmet need like glaucoma.”

“The distribution agreement and investment is an important milestone for Sanoculis, as it demonstrates Bausch + Lomb’s strong confidence in our technology. Together, they will enable Sanoculis to expand its presence and customer base in Europe. Bausch + Lomb’s extensive distribution footprint in Europe will ensure that many more glaucoma specialists and their patients have access to MIMS®“, said Nir Israel, co-founder and CEO of Sanoculis. “We believe that MIMS® will be a strong addition to Bausch + Lomb’s product portfolio and reinforce Bausch + Lomb’s leadership position in the surgical glaucoma segment. “

“Having operated on a dozen patients with MIMS® device and the procedure, I believe the device has a very short learning curve and is a safe alternative to stent procedures,” said ike ahmedMedical Director and Professor, Prism Eye Institute, Canada. “MIMS® can be easily used with cataract surgery and suitable for most glaucoma patients. The clinical data of Europe demonstrates similar efficacy to trabeculectomy with fewer side effects. Leaving nothing behind leaves the door open for future treatment options, which is a big plus. »

In addition, the companies have entered into an option agreement, under which Bausch + Lomb has an option to purchase all of the assets of Sanoculis.

About Sanoculis
Sanoculis Ltd. is a medical device start-up developing an innovative surgical procedure for the treatment of glaucoma. This procedure is safe, effective and simple to perform and aims to complement the surgical solutions currently available in a multi-billion international market. For more information about the company and MIMS® procedure, please visit www.sanoculis.com.

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every stage of life. Its comprehensive portfolio of over 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products, and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and sales footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, ON with headquarters in Bridgewater, New Jersey. For more information, visit www.bausch.com and contact us at TwitterLinkedIn, Facebook and Instagram.

Forward-looking statements
This press release may contain forward-looking statements, which can generally be identified by the use of the words “anticipates”, “hopes”, “expects”, “intends”, “expects”, “should ‘, ‘could’, ‘would’, ‘may’, ‘believes’, ‘estimates’, ‘potential’, ‘target’ or ‘continues’ and similar variations or expressions. These statements are based on management’s current expectations and beliefs and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the United States Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated into present by reference. They also include, but are not limited to, the risks and uncertainties caused by or related to the evolution of the COVID-19 pandemic, as well as the fear of this pandemic and its potential effects, including the severity, duration and future impact are highly uncertain and cannot be predicted, and which could have a material adverse impact on Bausch + Lomb, including, but not limited to, delays in its project development, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual results, except as required by law.

References

  1. World Glaucoma Association. Retrieved from Glaucoma Information Statistics – Glaucoma Information (glaucomapatients.org). Recovered July 19, 2022.

MIMS® is a registered trademark of Sanoculis.
All other product/brand names are trademarks of their respective owners.

© 2022 Bausch & Lomb Incorporated or its affiliates.

SOURCEBausch + Lomb Corporation

Comments are closed.